<DOC>
	<DOCNO>NCT03036046</DOCNO>
	<brief_summary>Non-randomized , multi-centre , open label , uncontrolled , multiple dose , phase IIa study . A total 18 patient diagnose acute myeloid leukaemia ( AML ) schedule chemotherapy expect neutropenic ( &lt; 500 Absolute neutrophil count ( ANC ) /µl ) &gt; 10 day treat . F901318 give conjunction fluconazole posaconzaole order ass safe treatment regimen combination .</brief_summary>
	<brief_title>Safety Pharmacokinetics Oral F901318 ( Fluconazole Posaconazole ) IN Aml Leukaemia</brief_title>
	<detailed_description>'F901318 potent vitro efficacy Aspergillus spp . include azole-resistant strain consistent efficacy vivo mouse model infection . F901318 active oral intravenous route administration preclinical efficacy study . Non-clinical study phase I clinical trial show F901318 good overall safety profile limited potential drug-drug interaction . F901318 exhibit highly promising profile potentially address critical treatment requirement invasive Aspergillus infection change clinical environment new class antifungal need . This phase IIa study aim confirm PK safety information F901318 phase I bridge neutropenic AML patient population , represent main population future efficacy trial . Coadministration fluconazole posaconazole allow recognize potential factor suboptimal F901318 exposure without risk fatal disseminate infection . '</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Posaconazole</mesh_term>
	<criteria>Participating patient need fulfil follow criterion : 1 . Patients diagnose AML enter treatment chemotherapy . 2 . Patients expect neutropenic ( ANC &lt; 500/µl ) &gt; 10 day . 3 . Provision write informed consent prior study specific procedure . 4 . Ability willingness comply protocol . 5 . Patients age 18 year . 6 . Patients body weight ≥60 kg 7 . Group F : patient receive accord local clinical standard either fungal prophylaxis topical fungal prophylaxis ( e.g . Ampho moronal® ) fluconazole routine fungal prophylaxis 8 . Group P : patient receive posaconazole fungal prophylaxis accord local clinical standard Any follow exclude patient study : 1 . Documented lung infiltrate screening . 2 . Evidence active fungal infection , document serum GMI ≥0.5 screening ( within 5 day study start ) 3 . Current IFD prior history IFD patient receive systemic antifungal therapy proven probable IFD last 12 month . 4 . Patients receive systemic antifungal therapy 72 hour immediately prior first administration study medication . Echinocandins , posaconazole ( group P , see also inclusion criterion 8 ) , topical polyenes nystatin acceptable . 5 . Concomitant exposure phenobarbital long act barbiturate , triazolam , carbamazepine , phenytoin , pimozide , cisaprid , efavirenz , ritonavir , rifabutin , rifampicin , ergot alkaloid ( ergotamine , dihydroergotamin ) , ibrutinib , idelalisib , vinca alkaloid , digoxin , dofetilide , quinidine , St. John´s wort , everolimus , sirolimus , astemizole , terfenadine , methadone , alfentanil , fentanyl structurally relate opiate , warfarin ( see also section 8.8 detail ) . 6 . Documented prolongation QTc interval ( &gt; 450 m ) . 7 . Concomitant medication prolongs QT interval ( except cytostatic drug use chemotherapy , mitoxantrone ) . 8 . Any concomitant medical condition , opinion investigator , may unacceptable additional risk patient he/she participate study . 9 . History convulsion . 10 . Female patient : Positive result pregnancy test breastfeeding . 11 . Female patient childbearing potential practice sexual abstinence common way life confirm stay sexually abstinent also participation study use agree use appropriate contraceptive method ( prior study , include 14 day last dose study therapy ) define ICH guideline M3 ( R2 ) nonclinical safety study conduct human clinical trial market authorisation pharmaceutical ( EMA/CPMP/ICH/286/1995 ) . Hormonal contraception alone consider appropriate . See section 9.3.2 additional information . 12 . Known hypersensitivity component study medication . 13 . A history additional risk factor Torsade de pointes ( e.g. , heart failure , hypokalaemia , cardiomyopathy , sinus bradycardia , symptomatic arrhythmia , family history long QT Syndrome ) . 14 . Patient acute hepatitis prior 6 month , chronic hepatitis , cirrhosis ( ChildPugh class ) , acute hepatic failure , acute decompensation chronic hepatic failure 15 . Presence hepatic disease indicate aspartate aminotransferase ( AST ) alanine transaminase ( ALT ) &gt; 3 × upper limit normal ( ULN ) Screening . Patients AST and/or ALT &gt; 3 × ULN &lt; 5 × ULN eligible elevation acute , accompanied total bilirubin ≥2xULN document investigator directly relate infectious process treat . During clinical study , investigator responsible , without delay , determine whether patient meet potential Hy 's law criterion ( accord FDA [ 16 ] ) . 16 . Patient total bilirubin &gt; 3 × ULN , unless isolate hyperbilirubinemia directly relate acute infection due know Gilbert 's disease . 17 . Calculated creatinine clearance ( CrCl ) &lt; 50 mL/minute . 18 . Medical history oliguria ( &lt; 20 mL/h ) unresponsive fluid challenge . 19 . Suspected additional cause neutropenia immunosuppression ( AML myelodysplastic syndrome ) . 20 . Any medical condition , may affect clinical evaluability patient . 21 . Patients previously enrol study . 22 . Patient participate intend participate clinical study involve administration investigational medication time presentation , course study , 30 day prior study start . New combination label substance chemotherapy allow . 23 . Chronic external ocular disease 24 . Contact lens use intend study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>